The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes |
Jan 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
Genetics of Progression From MDS to Secondary Leukemia |
May 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
Clinical decision‐making and treatment of myelodysplastic syndromes |
Oct 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
Oct 2023 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse |
Jul 2020 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study |
May 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study |
Dec 2023 |
Blood Advances |
Aplastic Anemia |
Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria |
Jun 2023 |
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |